Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT

BENEFIT and BENEFIT‐EXT were phase III studies of cytotoxic T‐cell crossmatch–negative kidney transplant recipients randomized to belatacept more intense (MI)‐based, belatacept less intense (LI)‐based, or cyclosporine‐based immunosuppression. Following study completion, presence/absence of HLA‐speci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Transplant
Main Authors: Bray, R. A., Gebel, H. M., Townsend, R., Roberts, M. E., Polinsky, M., Yang, L., Meier‐Kriesche, H.‐U., Larsen, C. P.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Brief Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055813/
https://ncbi.nlm.nih.gov/pubmed/29573335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14738
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados